ELITE PHARMACEUTICALS INC /NV/ (ELTP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 60M 120M 180M Q2 '22: 26.1M Q3 '22: 29M Q4 '22: 32.3M Q1 '23: 32.9M Q2 '23: 32.9M Q3 '23: 33.2M Q4 '23: 34.2M Q1 '24: 35.5M Q2 '24: 41M Q3 '24: 47.3M Q4 '24: 56.6M Q1 '25: 66.4M Q2 '25: 71.2M Q3 '25: 70M Q4 '25: 84M Q1 '26: 105.5M Q2 '26: 122.9M Q3 '26: 140.1M Q4 '26: 148.9M Q1 '27: 141M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Gross Profit TTM

0 30M 60M 90M Q2 '22: 12.6M Q3 '22: 13.2M Q4 '22: 14.8M Q1 '23: 15.2M Q2 '23: 15.3M Q3 '23: 16.2M Q4 '23: 16.2M Q1 '24: 16.9M Q2 '24: 19.6M Q3 '24: 21.7M Q4 '24: 26.4M Q1 '25: 30.1M Q2 '25: 31.8M Q3 '25: 30.9M Q4 '25: 40.1M Q1 '26: 58.8M Q2 '26: 64.7M Q3 '26: 71.5M Q4 '26: 75M Q1 '27: 61.3M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Income TTM

-20M 0 20M 40M 60M Q2 '20: -6.2M Q3 '20: -2.9M Q4 '20: -2.3M Q1 '21: -307.1K Q2 '21: 1.5M Q3 '21: 1.8M Q4 '22: 5.1M Q1 '23: 5.1M Q2 '23: 4.8M Q3 '23: 4.9M Q4 '24: 10.8M Q1 '25: 13.1M Q2 '25: 14.6M Q3 '25: 12.2M Q4 '25: 19.6M Q1 '26: 37.4M Q2 '26: 42.2M Q3 '26: 50.1M Q4 '26: 49.1M Q1 '27: 34.9M Q3 '20 Q2 '21 Q1 '23 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Net Income TTM

-20M 0 20M 40M 60M Q2 '20: -6.3M Q3 '20: -5.8M Q4 '20: -2.2M Q1 '21: -1.4M Q2 '21: 2.6M Q3 '21: 6.5M Q4 '22: 8.9M Q1 '23: 6.8M Q2 '23: 6.5M Q3 '23: 7.2M Q4 '24: 20.1M Q1 '25: 19.6M Q2 '25: -6.4M Q3 '25: -18M Q4 '25: -4.3M Q1 '26: -10.8M Q2 '26: 13.9M Q3 '26: 43.4M Q4 '26: 44.9M Q1 '27: 56.7M Q3 '20 Q2 '21 Q1 '23 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Cost of Revenue TTM

0 30M 60M 90M Q2 '22: 13.5M Q3 '22: 15.8M Q4 '22: 17.5M Q1 '23: 17.7M Q2 '23: 17.7M Q3 '23: 17M Q4 '23: 18M Q1 '24: 18.5M Q2 '24: 21.5M Q3 '24: 25.6M Q4 '24: 30.3M Q1 '25: 36.4M Q2 '25: 39.3M Q3 '25: 39.1M Q4 '25: 44M Q1 '26: 46.6M Q2 '26: 58.2M Q3 '26: 68.6M Q4 '26: 73.8M Q1 '27: 79.7M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Cash Flow TTM

-9M 0 9M 18M 27M Q2 '21: 1.2M Q3 '21: 2.7M Q4 '22: 6.5M Q1 '23: 4.2M Q2 '23: 5.6M Q3 '23: 2M Q4 '23: 3.3M Q1 '24: 1.2M Q2 '24: -544.9K Q3 '24: -2.4M Q4 '24: -3.2M Q1 '25: 2.6M Q2 '25: 4.3M Q3 '25: 5.6M Q4 '25: 7.5M Q1 '26: 19.1M Q2 '26: 22.7M Q3 '26: 18.5M Q4 '26: 23.7M Q1 '27: 19M Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Free Cash Flow TTM

-8M 0 8M 16M 24M Q4 '19: -6.8M Q1 '20: -5.1M Q2 '20: -3.7M Q3 '20: -2.7M Q4 '20: -1.8M Q1 '21: -1.2M Q2 '21: 1.1M Q3 '21: 2.6M Q4 '22: 6M Q1 '23: 3.6M Q2 '23: 31K Q3 '23: -3.5M Q4 '23: -2.4M Q3 '25: 4.4M Q4 '25: 5.8M Q1 '26: 18M Q2 '26: 21.7M Q3 '26: 17.2M Q4 '26: 22.8M Q1 '27: 17.5M Q1 '20 Q4 '20 Q3 '21 Q2 '23 Q3 '25 Q2 '26 Q1 '27

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 400M 800M 1.2B Q3 '20: 829.4M Q1 '21: 1B Q2 '21: 913.6M Q3 '21: 1B Q1 '22: 1B Q2 '22: 1B Q3 '22: 1B Q1 '23: 1B Q2 '23: 1B Q3 '23: 1B Q1 '24: 1B Q2 '24: 1B Q3 '24: 1B Q1 '25: 1.1B Q2 '25: 1.1B Q3 '25: 1.1B Q1 '26: 1.1B Q2 '26: 1.1B Q3 '26: 1.1B Q1 '27: 1.1B Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.03 -0.01 0.00 0.01 0.03 0.04 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.01 Q1 '23: 0.01 Q2 '23: 0.01 Q3 '23: 0.01 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.01 Q3 '24: 0.01 Q4 '24: 0.01 Q1 '25: 0.01 Q2 '25: -0.01 Q3 '25: -0.02 Q4 '25: 0.00 Q1 '26: -0.01 Q2 '26: 0.01 Q3 '26: 0.03 Q4 '26: 0.02 Q1 '27: 0.04 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.